Number of patients

42

Efficacy

Complete response (CR), n (%)

6 (14%)

Partial response (PR), n (%)

22 (52%)

Disease control (CR + PR + NC^*), n (%)

35 (83%)

PFS, months (median)

7.7 (5.5-9.7)

OS, months (median)

11.8 (7.6-15.2)

Reason for discontinuation of DOX

Completed planned number of DOX

14 (33%)

Progressive Disease

11 (26%)

Toxicity or patients wish

17 (41%)

Dose administration

Number of DOX (median, IQR)

6 (4-8)

Number of docetaxel cycles (median, IQR)

6 (4-8)

Cumulative dose of D, (median, IQR)

308 (204-350)

Dose intensity of D

97 (94-100)

Cumulative dose of O, (median, IQR)

426 (305-592)

Dose intensity of O, (median, IQR)

96 (82-100)

Duration of therapy, months (median, IQR)

4.8 (3.0-5.5)